Sterling Capital Management’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
LCM
Sterling Capital Management's CCCC Position: Q3 2026 in Review
Sterling Capital Management reduced its C4 Therapeutics (CCCC) stake by 2% in Q3 2026, selling an estimated $153 and leaving 2,002 shares worth $6.67K. The position accounts for ﹤0.01% of the portfolio, ranked #2728.
Sterling Capital Management first reported a position in CCCC in Q3 2024 and has held it in 5 quarters since. The position peaked at $9.5K in Q2 2026. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.
- Sterling Capital Management held 2,002 shares of C4 Therapeutics worth $6.67K as of Q3 2026.
- Sterling Capital Management sold 41 C4 Therapeutics shares in Q3 2026, an estimated $153.
- C4 Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2728 holding.
- Sterling Capital Management first reported a position in C4 Therapeutics in Q3 2024 and has held it in 5 quarters since.
- Sterling Capital Management's C4 Therapeutics position peaked at $9.5K in Q2 2026.
- 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.